Designing Tomorrow´s Vaccines

SVF Vaccines develops vaccines and immunotherapies to prevent and treat life-threatening diseases based on technology developed at Karolinska Institute in Stockholm. Our most advanced program is a therapeutic vaccine for chronic hepatitis D and B infections, while Karolinska Institutet and the OpenCorona consortium have recently completed a successful Phase 1 study with SVF Vaccines' universal Covid-19 vaccine. In addition, the Karolinska Institutet are using the same technology in a new phase I clinical trial for a vaccine against Crimean Congo Hemorrhagic Fever funded by the European Commission and the CCHF Vaccine consortium. Additional vaccines are in the discovery phase.